Clinical Trials Sponsored by Neurogene Inc.

Total 35428 results

Neurogene Inc.

Recruiting

Gene Therapy Study for Children With CLN5 Batten Disease (CLN5-200)

Neuronal Ceroid Lipofuscinosis CLN5

United States, United Kingdom
Neurogene Inc.

Recruiting

A Natural History Study of Neuronal Ceroid Lipofuscinosis Type 5 (CLN5)

Ceroid Lipofuscinosis, Neuronal 5

United States
Neurogene Inc.

Terminated

A Natural History Study of Aspartylglucosaminuria (AGU)

Lysosomal Storage Diseases | Aspartylglucosaminuria | Aspartylglucosamidase (AGA) Deficiency

United States
Neurogene Inc.

Recruiting

A Novel, Regulated Gene Therapy (NGN-401) Study for Female Children With Rett Syndrome

Rett Syndrome

United States
Neurogene Inc.

Terminated

A Natural History Study of Charcot-Marie-Tooth 4J (CMT4J) (CMT4J)

Charcot-Marie-Tooth Disease | Hereditary Motor and Sensory Neuropathy IV

United States
Neurolens Inc.

Completed

Neurolens Headache Study

Headache | Computer Vision Syndrome | Convergence Insufficiency | Binocular Vision Disorder

United States
Neurolens Inc.

Terminated

Neurolens Convergence Insufficiency Study

Computer Vision Syndrome | Convergence Insufficiency | Binocular Vision Disorder

United States
Neurogene Inc.
Merck Sharp & Dohme LLC

Active, not recruiting

NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer

Solid Tumor | Advanced Solid Tumor

United States, Australia, Canada
Neogene Therapeutics, Inc.

Recruiting

A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation

Endometrial Cancer | Non-small Cell Lung Cancer | Pancreatic Ductal Adenocarcinoma | Colorectal Carcinoma | Solid Tumor, Adult | KRAS G12D

United States
Neogene Therapeutics, Inc.

Recruiting

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Breast Cancer | Pancreatic Adenocarcinoma | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Colorectal Carcinoma | Other Solid Tumors

United States
Neurogen Corporation

Terminated

Efficacy and Safety Study of Aplindore in Patients With Restless Legs Syndrome

Restless Legs Syndrome

United States
Neurogen Corporation

Terminated

Efficacy and Safety Study of Aplindore in Patients With Early Parkinson Disease

Early Parkinson Disease

United States
NeurogesX

Completed

Study of NGX-1998 for the Treatment of Postherpetic Neuralgia

Pain | Postherpetic Neuralgia

United States
NeurogesX

Completed

Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy (HIV-AN) or Postherpetic Neuralgia (PHN)

HIV Infections | Pain | Peripheral Nervous System Diseases | Neuralgia | Herpes Zoster
NeurogesX

Completed

Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia

Pain | Peripheral Nervous System Diseases | Neuralgia | Herpes Zoster

United States
NeurogesX

Completed

Tolerability of Three Local Anesthetic Formulations in Conjunction With NGX-4010 for the Treatment of Neuropathic Pain

HIV Infections | Pain | Diabetes Mellitus | Diabetic Neuropathies | Peripheral Nervous System Diseases | Neuralgia | Herpes Zoster | Polyneuropathies

United States
Neurogen Corporation

Terminated

Efficacy and Safety Study of Adipiplon, Placebo and an Active Control in Primary Insomniacs

Primary Insomnia

United States
NeurogesX

Completed

Study of NGX-4010 With the Use of Open Label Lidocaine (2.5%)/Prilocaine (2.5%) Cream for the Treatment of Postherpetic Neuralgia (PHN)

Postherpetic Neuralgia

United States
NeurogesX

Completed

Effect of NGX-4010 on ENFD and Sensory Function

Human Volunteers

United States
NeurogesX

Completed

NGX-4010 for the Treatment of Postherpetic Neuralgia

Pain | Peripheral Nervous System Diseases | Neuralgia | Herpes Zoster | Shingles

United States
NeurogesX

Completed

Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy

HIV Infections | Pain | Peripheral Nervous System Diseases

United States
NeurogesX

Completed

Study of Three Capsaicin Dermal Liquid Formulations on Epidermal Nerve Fiber Immunostaining and Sensory Function

Pain
NeurogesX

Terminated

Study of NGX-4010 for Treatment of Painful HIV-Associated Neuropathy

HIV Infections | Pain | Peripheral Nervous System Diseases

United States
NeurogesX

Completed

Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy

HIV Infections | Pain | Peripheral Nervous System Diseases
NeurogesX

Completed

A Study to Investigate the Tolerability and Effects on Epidermal Nerve Fiber Density of Multiple Low-Concentrations of NGX-1998 in Healthy Volunteers

Pain

United States
NeurogesX

Completed

Study of NGX-4010 for the Treatment of Postherpetic Neuralgia

Pain | Peripheral Nervous System Diseases | Neuralgia | Herpes Zoster | Shingles
NeurogesX

Completed

Study of NGX-4010 for the Treatment of Postherpetic Neuralgia

Pain | Peripheral Nervous System Diseases | Neuralgia | Herpes Zoster | Shingles
NeurogesX

Unknown

Pilot Study of High-Concentration Capsaicin Patches in the Treatment of Painful HIV-Associated Neuropathy

HIV Infections

United States
NeurogesX

Completed

Pilot Study of High-Dose Capsaicin Patches to Treat Postherpetic Neuralgia Pain

Pain | Peripheral Nervous System Diseases | Neuralgia | Herpes Zoster

United States
NeurogesX

Terminated

An Open-Label Extension Study of NGX-4010 for the Treatment of Neuropathic Pain

HIV Infections | Pain | Diabetes Mellitus | Diabetic Neuropathies | Peripheral Nervous System Diseases | Neuralgia | Herpes Zoster | Polyneuropathies
Dr. Matthew Kennedy

Not yet recruiting

EEG-guided Cognitive Pacing Tool During Concussion Recovery

Concussion, Brain
Neuroglee Therapeutics

Completed

Effectiveness and Safety of a Digitally Based Multidomain Intervention for Mild Cognitive Impairment

Mild Cognitive Impairment

Singapore
Neurotune AG

Unknown

Dimiracetam in Painful Neuropathies Affecting AIDS Patients (DIPANAP)

Acquired Immunodeficiency Syndrome

Switzerland
NeuroSense Therapeutics Ltd.

Active, not recruiting

A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS (PARADIGM)

Amyotrophic Lateral Sclerosis | ALS

Israel, Italy, Canada
NeuroSense Therapeutics Ltd.

Recruiting

A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease. (RoAD)

Alzheimer Disease

Israel
NeuroSense Therapeutics Ltd.

Completed

A Multiple-Dose PK Study to Evaluate the Comparative Bioavailability of PrimeC Tablets to Ciprofloxacin Tablets Co-administered With Celecoxib Capsules, in Healthy Adult Subject

Pharmacokinetics

United States
NeuroSense Therapeutics Ltd.

Completed

A Pilot Study to Evaluate the PK Profile of PrimeC-ER Tablets in Healthy Adult Subjects

Pharmacokinetics

United States
NeuroSense Therapeutics Ltd.

Completed

Ciprofloxacin/Celecoxib Combination in Patients With ALS

ALS (Amyotrophic Lateral Sclerosis)

United States
NeuroSense Therapeutics Ltd.

Completed

Open Label Study to Evaluate Ciprofloxacin/Celecoxib Combination in Patients With ALS

Amyotrophic Lateral Sclerosis | ALS

Israel
Neurogen Brain and Spine Institute

Withdrawn

Cell Therapy in Limb Girdle Muscular Dystrophy

Limb Girdle Muscular Dystrophy

India
Neurogen Brain and Spine Institute

Withdrawn

Safety and Efficacy of Autologous Stem Cell Therapy in Chronic Stroke

Cerebrovascular Accident

India
Neurogen Brain and Spine Institute

Withdrawn

Stem Cell Therapy for Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

India
Neurogen Brain and Spine Institute

Withdrawn

Stem Cell Therapy in Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

India
Neurogen Brain and Spine Institute

Withdrawn

Safety and Efficacy of Stem Cell Therapy in Spinal Cord Injury

Spinal Cord Injury

India
Neurogen Brain and Spine Institute

Withdrawn

Stem Cell Therapy in Muscular Dystrophy

Muscular Dystrophy

India
Neurogen Brain and Spine Institute

Withdrawn

Stem Cell Therapy in Mental Retardation

Mental Retardation

India
Neurogen Brain and Spine Institute

Withdrawn

Cell Therapy as Treatment for Cerebral Palsy

Cerebral Palsy

India
Neurogen Brain and Spine Institute

Withdrawn

Stem Cell Therapy in Spinal Cord Injury

Spinal Cord Injury

India
Neurogen Brain and Spine Institute

Withdrawn

Stem Cell Therapy in Limb Girdle Muscular Dystrophy

Limb Girdle Muscular Dystrophy

India
Neurogen Brain and Spine Institute

Withdrawn

Stem Cell Therapy in Autism Spectrum Disorders

Autism Spectrum Disorders

India

Clinical Trials Sponsored by Neurogene Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations